SCHEMBL6693291

SCHEMBL6693291

COC(=O)CNc1nc(F)c(Cl)c(Oc2ccc(O)c(S(=O)(=O)Nc3ccc(F)cc3)c2)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.38
▸ LMNA P02545 3/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ PIK3CD O00329 1/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ PIK3C3 Q8NEB9 1/20 0.35
▸ HSD17B3 P37058 1/20 0.35
▸ HSD17B2 P37059 1/20 0.35
▸ POLB P06746 2/20 0.35
▸ IDH1 O75874 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6690024 0.91 SMN1; SMN2 (0.48) LMNAHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL6694254 0.81 CA12 (0.34) THRBLMNAMEN1KMT2AHSD17B3
SCHEMBL6694244 0.80 THRB (0.41) THRBLMNAHPGDSMN1; SMN2MAPT
SCHEMBL6692436 0.79 ATM (0.39) THRBMEN1KMT2AMAPTTSHR
SCHEMBL6695481 0.78 THRA (0.37) THRB
SCHEMBL7258380 0.78 THRA (0.39) THRBALDH1A1
SCHEMBL6692377 0.76 LMNA (0.58) THRBLMNAHPGDSMN1; SMN2MEN1
SCHEMBL6699450 0.76 THRB (0.39) THRBLMNAHPGDSMN1; SMN2KMT2A
SCHEMBL6697155 0.76 L3MBTL1 (0.39) THRBLMNAHPGDMEN1KMT2A
SCHEMBL6692440 0.74 THRB (0.36) THRBLMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747048-B2 TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, BRISTOL-MYERS SQUIBB COMPANY 2004-06-08 — — US disclosed
US-20040039028-A1 Pyridine-based thyroid receptor ligands BRISTOL-MYERS SQUIBB COMPANY 2004-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039028-A1 Pyridine-based thyroid receptor ligands TSHR, THRB, THRA THRB 2/4885LMNA 4794/4885HPGD 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback